4 research outputs found

    Oral Corticosteroid Use and the Risk of Acute Myocardial Infarction in Chronic Obstructive Pulmonary Disease

    Get PDF
    BACKGROUND: Given the limited efficacy of oral corticosteroids in treating chronic obstructive pulmonary disease (COPD), the possible cardiac side effects of oral corticosteroids are of particular concern in an elderly population. The impact of the use of oral corticosteroids on the risk of acute myocardial infarction (AMI) in a cohort of patients with COPD was studied

    Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease

    No full text
    BACKGROUND: Given the limited efficacy of oral corticosteroids in treating chronic obstructive pulmonary disease (COPD), the possible cardiac side effects of oral corticosteroids are of particular concern in an elderly population. The impact of the use of oral corticosteroids on the risk of acute myocardial infarction (AMI) in a cohort of patients with COPD was studied

    Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases

    No full text
    International audienceOBJECTIVE:Unlike several other national health agencies, French health authorities recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as second choice for the treatment of newly diagnosed non-valvular atrial fibrillation (NVAF), with vitamin K antagonists (VKA) remaining the first choice. We investigated the patterns of use of DOACs versus VKA in the treatment of NVAF in France over the first 5 years of DOAC availability. We also identified the changes in patient characteristics of those who initiated DOAC treatment over this time period.METHODS:Based on the French National Health Administrative Database, we constituted a population-based cohort of all patients who were newly treated for NVAF between January 2011 and December 2015. Trends in drug use were described as the percentage of patients initiating each drug at the time of treatment initiation. A multivariate analysis using logistic regression model was performed to identify independent sociodemographic and clinical predictors of initial anticoagulant choice.RESULTS:The cohort comprised 814 446 patients who had received a new anticoagulant treatment for NVAF. The proportion of patients using DOACs as initial anticoagulant therapy reached 54% 3 months after the Health Ministry approved the reimbursement of dabigatran for NVAF, and 61% by the end of 2015, versus VKA use. In the multivariate analysis, we found that DOAC initiators were younger and healthier overall than VKA initiators, and this tendency was reinforced over the 2011-2014 period. DOACs were more frequently prescribed by cardiologists in 2012 and after (adjusted OR in 2012: 2.47; 95% CI 2.40 to 2.54).CONCLUSION:Despite recommendations from health authorities, DOACs have been rapidly and massively adopted as initial therapy for NVAF in France. Observational studies should account for the fact that patients selected to initiate DOAC treatment are healthier overall, as failure to do so may bias the risk-benefit assessment of DOACs

    Determination of central blood pressure by a noninvasive method (brachial BP and QKD interval)

    No full text
    Background: The measurement of central blood pressure (BPc) has become a matter of importance. Several therapeutic trials have noted a different protective effect against cardiovascular complications with different antihypertensive strategies, but an identical decrease in brachial BP (BPb). A possible explanation lies in the different effects of the treatments on BPc. We propose a new noninvasive method for the automatic measurement of BPc based on the QKD interval, an arterial stiffnes s marker. Materials and Methods: This study was carried out on patients referred for cardiac catheterization. We simultaneously measured the central SBP (SBPc) invasively with a pigtail probe, and the BPb by a cuff coupled with recording of the QKD interval. Two cohorts were studied, one to define an algorithm of SBPc estimation and one to validate this algorithm. Results: The first cohort included 65 patients. We performed 136 simultaneous measurements. In the multivariate analysis, four variables were significantly correlated with SBPc: mean BPb (mBPb), QKD, height and heart rate (HR) with the following regression equation: SBP = 105 + 1.29 × mBPb-0.39 × HR-0.30 × height-0.11 × QKD This equation estimated 81% of the variance of the invasive SBPc±13mmHg. This algorithm was then tested in another cohort of 80 patients. Difference between measured and estimated SBPc was 2±14mmHg. Conclusion: This study showed that it is possible to estimate SBPc by simultaneous measurement of QKD and BPb. If further studies confirm these results, a noninvasive ambulatory method of monitoring of SBPc could be employed in clinical practice.7 page(s
    corecore